(Q37815614)

23 August 2017

1 reference

title

Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer (English)

1 reference

23 August 2017

F Piacentini

4

0 references

author name string

V Guarneri

1

1 reference

23 August 2017

E Barbieri

2

1 reference

23 August 2017

M V Dieci

3

1 reference

23 August 2017

P Conte

5

1 reference

23 August 2017

publication date

1 November 2010

1 reference

23 August 2017

published in

Cancer Treatment Reviews

1 reference

23 August 2017

volume

36 Suppl 3

1 reference

23 August 2017

page(s)

S62-6

1 reference

Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970022-0

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970022-0

7 January 2021

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970022-0

7 January 2021

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970022-0

7 January 2021

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970022-0

7 January 2021

Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970022-0

7 January 2021

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970022-0

7 January 2021

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970022-0

7 January 2021

Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970022-0

7 January 2021

Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970022-0

7 January 2021

Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970022-0

7 January 2021

Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970022-0

7 January 2021

Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970022-0

7 January 2021

Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970022-0

7 January 2021

Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970022-0

7 January 2021

Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970022-0

7 January 2021

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970022-0

7 January 2021

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970022-0

7 January 2021

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970022-0

7 January 2021

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970022-0

7 January 2021

Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970022-0

7 January 2021

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970022-0

7 January 2021

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970022-0

7 January 2021

Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970022-0

7 January 2021

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970022-0

7 January 2021

Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278).

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970022-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970022-0

7 January 2021

Trastuzumab: triumphs and tribulations

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970022-0

7 January 2021

Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS0305-7372%2810%2970022-0

7 January 2021

10.1016/S0305-7372(10)70022-0

Identifiers

DOI

1 reference

23 August 2017

1 reference